No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CABA240719C5000
- 2.00
- -0.40-16.67%
15min DelayClose Jul 19 15:58 ET
2.00High2.00Low
2.00Open2.40Pre Close1 Volume1 Open Interest5.00Strike Price200.00Turnover7320.45%IV-1.27%PremiumJul 19, 2024Expiry Date2.09Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8000Delta0.0532Gamma2.38Leverage Ratio-20.0867Theta0.0000Rho1.91Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering.Kaival Brands priced its 3,921,50
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday.Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million sh
Cantor Fitzgerald Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $50
Cantor Fitzgerald analyst Joshua Schimmer maintains $Cabaletta Bio(CABA.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 51.6
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Comments
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
23
$Cabaletta Bio(CABA.US$ isn't it great that we now punish good stocks with good news... they need to fix this crap, all these meidcal companies rely a lot on share prices...
Read more
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?